Global antisense and RNAi therapeutic
market is expected to witness a lucrative growth rate during the
forecast period owing to rising prevalence of infectious diseases, and coronary
heart disorders which lead to cardiovascular diseases. Incorporation of
technologically advanced RNA based technologies such as RNA antisense; RNA
nanobiotechnologies, RNA interference, and SMaRT technology are also expected
to drive market demand. Furthermore, growing needs for high throughput
therapeutic tools for treatment of neurometabolic disorders such
as amyotrophic lateral sclerosis, Huntington’s disease and Alzheimer’s
disease, and rising awareness regarding tissue specificity for drug delivery
about RNA based drugs are factors expected to fuel the growth for gene synthesizing
mechanisms & cellular gene silencing. However, huge investment requirement
in drug delivery & research and high treatment success rates are some
factors that are expected to boost market growth.
To request a
sample copy or view summary of this report, click the link below:
Further key findings from the study suggest:
Increasing awareness
towards the use of aptamers and ribozymes for suppression of target genes, and
there selective expression in order to treat diseases at a genomic level prior
to protein expression is also expected to promote the market growth. Increasing
usage of RNAi technology based therapeutics for infectious diseases such as
HIV, viral hepatitis and cancer in order to overcome the adverse effects
observed by consumption of generic drugs and inhibit the metabolic growth of
causative micro-organism are expected to drive demand for antisense & RNAi
therapeutic market through to 2022. Furthermore, approval of different novel
drugs for the treatment of cholesterol associated disorders and ocular diseases
are anticipated to have a positive impact on the growth of this market in the
coming seven years.
The geographical
analysis of antisense & RNAi therapeutic market divides it into Europe,
North America, Asia-Pacific, Latin America and MEA. North America held the
largest share in market revenue in 2014 as a consequence of rise in incidence
of cardiovascular, genetic and neurometabolic disorders. Other factors
contributing towards large market share of the region include rise in number of
R&D institutes and laboratories involved in development of bioinformatics
based research for disease prognosis. However, Asia Pacific region with
emerging economies such as India and China is expected to grow at a
significantly faster rate in the RNAi and antisense therapeutic market. Factors
attributing this anticipated growth of this region include presence of unmet
market demand, and increased used of miRNA as a disease marker for oncology
diseases. Furthermore, presence of many antisense and siRNA molecules in the
pipeline for drug development under clinical trials for regulatory approval is
expected to fuel the market growth during the forecast period. Key participants
in the market include Sanofi, Allergan, Benitec Biopharma, Biogen, Atlantic
Pharmaceuticals, Inc., Enzon Pharmaceuticals Inc., AstraZeneca, Bristol-Myers Squibb,
Acuitas Therapeutics, Glaxosmithkline, Isis Pharmaceuticals, Dicerna
Pharmaceuticals, Antisense Therapeutics, Dainippon Sumitomo Pharma, Roche
Holding AG and Tekmira Pharmaceuticals. Competitive strategies adopted by the
market players include collaborations for development and commercialization of
antisense and RNAi drugs in the pharmaceutical and biotechnological market.
See More
Reports of This Category:
About
Grand View Research:
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, we offer market intelligence studies
ensuring relevant and fact-based research across a range of industries, from
technology to chemicals, materials and healthcare.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email:
sales@grandviewresearch.com
No comments:
Post a Comment